Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Palumbo, K. Anderson (2011)
Multiple myeloma.The New England journal of medicine, 364 11
P Moreau (2013)
10.1093/annonc/mdt297Ann Oncol., 24
BGM Durie (2006)
10.1038/sj.leu.2404284Leukemia, 20
(2015)
An open-label, multicenter, phase 1B study of daratumumab in combination with pomalidomide-dexamethasone and with backbone regimens in patients with multiple myeloma
M. Weers, Y. Tai, M. Veer, J. Bakker, T. Vink, D. Jacobs, L. Oomen, M. Peipp, T. Valerius, J. Slootstra, T. Mutis, W. Bleeker, K. Anderson, H. Lokhorst, J. Winkel, P. Parren (2011)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological TumorsThe Journal of Immunology, 186
A. Palumbo, A. Chanan-Khan, K. Weisel, A. Nooka, T. Masszi, M. Beksaç, I. Špička, V. Hungria, M. Munder, M. Mateos, T. Mark, M. Qi, Jordan Schecter, H. Amin, X. Qin, W. Deraedt, T. Ahmadi, A. Spencer, P. Sonneveld (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.The New England journal of medicine, 375 8
J. Harousseau, M. Dreyling (2010)
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology, 21 Suppl 5
Shaji Kumar, M. Dimopoulos, E. Kastritis, E. Terpos, H. Nahi, H. Goldschmidt, J. Hillengass, X. Leleu, M. Beksaç, M. Alsina, A. Oriol, M. Cavo, E. Ocio, M. Mateos, E. O’Donnell, R. Vij, H. Lokhorst, N. Donk, C. Min, T. Mark, I. Turesson, M. Hansson, H. Ludwig, S. Jagannath, M. Delforge, C. Kyriakou, P. Hari, U. Mellqvist, S. Usmani, D. Dytfeld, A. Badros, P. Moreau, Kihyun Kim, P. Otero, Jae Lee, C. Shustik, Daniel Waller, W. Chng, S. Ozaki, Je-Jung Lee, J. Rubia, H. Eom, L. Rosiñol, J. Lahuerta, A. Sureda, Jin Kim, B. Durie (2016)
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG studyLeukemia, 31
M. Veer, M. Weers, B. Kessel, J. Bakker, S. Wittebol, P. Parren, H. Lokhorst, T. Mutis (2011)
The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapiesBlood Cancer Journal, 1
Naresh Kumar, A. Zaw, M. Reyes, R. Malhotra, Pang Wu, M. Makandura, J. Thambiah, Gabriel Liu, H. Wong (2015)
Versatility of Percutaneous Pedicular Screw Fixation in Metastatic Spine Tumor Surgery: A Prospective AnalysisAnnals of Surgical Oncology, 22
M. Dimopoulos, R. Orlowski, T. Facon, P. Sonneveld, K. Anderson, M. Beksaç, L. Benboubker, H. Roddie, A. Potamianou, C. Couturier, Huaibao Feng, O. Ataman, H. Velde, P. Richardson (2015)
Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myelomaHaematologica, 100
Lisa Raedler (2016)
Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma.American health & drug benefits, 9 Spec Feature
B. Durie, J. Harousseau, J. Miguel, J. Bladé, B. Barlogie, K. Anderson, M. Gertz, M. Dimopoulos, J. Westin, P. Sonneveld, H. Ludwig, G. Gahrton, M. Beksaç, J. Crowley, A. Belch, M. Boccadaro, I. Turesson, D. Joshua, D. Vesole, R. Kyle, R. Alexanian, G. Tricot, M. Attal, G. Merlini, R. Powles, P. Richardson, K. Shimizu, P. Tosi, G. Morgan, SV Group (2006)
International uniform response criteria for multiple myelomaLeukemia, 20
JF San Miguel (2008)
10.1056/NEJMoa0801479N Engl J Med, 359
M. Kropff, G. Bisping, Doris Wenning, S. Volpert, J. Tchinda, W. Berdel, J. Kienast (2005)
Bortezomib in combination with dexamethasone for relapsed multiple myeloma.Leukemia research, 29 5
JF San Miguel, R Schlag, NK Khuageva, MA Dimopoulos, O Shpilberg, M Kropff (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myelomaN Engl J Med, 359
S. Iida, Kenshi Suzuki, S. Kusumoto, M. Ri, N. Tsukada, Y. Abe, M. Aoki, Mitsuo Inagaki (2017)
Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation studyInternational Journal of Hematology, 106
S. Rajkumar, J. Harousseau, B. Durie, Kenneth Anderson, M. Dimopoulos, R. Kyle, J. Bladé, P. Richardson, R. Orlowski, D. Siegel, S. Jagannath, T. Facon, H. Avet-Loiseau, S. Lonial, A. Palumbo, J. Zonder, H. Ludwig, D. Vesole, O. Sezer, Nikhil Munshi, J. Miguel (2011)
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.Blood, 117 18
R. Comenzo, P. Moreau, M. Mateos, J. Bladé, L. Benboubker, J. Rubia, T. Facon, J. Fay, X. Qin, T. Masterson, Jordan Schecter, T. Ahmadi, J. San-Miguel (2015)
Abstract CT320: An open-label, multicenter, phase Ib study of daratumumab in combination with backbone regimens in patients with multiple myelomaCancer Research, 75
(2017)
DarzalexTM (daratumumab): prescribing information. 2016
J. Endell, C. Samuelsson, R. Boxhammer, S. Strauss, S. Steidl (2011)
Effect of MOR202, a human CD38 antibody, in combination with lenalidomide and bortezomib, on bone lysis and tumor load in a physiologic model of myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
R. Orlowski, T. Facon, P. Sonneveld, K. Anderson, M. Beksaç, L. Benboubker, H. Roddie, A. Potamianou, C. Couturier, Huaibao Feng, O. Ataman, H. Velde, P. Richardson (2013)
Retrospective Matched-Pair Analysis Of The Efficacy and Safety Of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients (Pts) With Relapsed Multiple Myeloma (MM)Blood, 122
Shuji Ozaki, Hiroshi Handa, T. Saitoh, Hirokazu Murakami, Mitsuhiro Itagaki, H. Asaoku, Kenshi Suzuki, A. Isoda, Morio Matsumoto, M. Sawamura, J. Konishi, K. Sunami, Naoki Takezako, S. Hagiwara, Yoshiaki Kuroda, T. Chou, E. Nagura, K. Shimizu (2015)
Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of MyelomaBlood Cancer Journal, 5
P. Sonneveld, H. Goldschmidt, L. Rosiñol, J. Bladé, J. Lahuerta, M. Cavo, P. Tacchetti, E. Zamagni, M. Attal, H. Lokhorst, A. Desai, A. Cakana, K. Liu, H. Velde, D. Esseltine, P. Moreau (2013)
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 26
J. Krejcik, J. Krejcik, T. Casneuf, I. Nijhof, Bie Verbist, Jaime Bald, T. Plesner, K. Syed, K. Liu, N. Donk, B. Weiss, T. Ahmadi, H. Lokhorst, T. Mutis, A. Sasser (2016)
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.Blood, 128 3
M. Gordon (2009)
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple MyelomaYearbook of Oncology, 2009
H. Lokhorst, T. Plesner, J. Laubach, H. Nahi, P. Gimsing, M. Hansson, M. Minnema, U. Lassen, U. Lassen, J. Krejcik, A. Palumbo, N. Donk, T. Ahmadi, I. Khan, C. Uhlar, Jianping Wang, A. Sasser, N. Losic, S. Lisby, L. Basse, N. Brun, P. Richardson (2015)
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.The New England journal of medicine, 373 13
S. Lonial, B. Weiss, S. Usmani, S. Singhal, A. Chari, N. Bahlis, A. Belch, A. Krishnan, R. Vescio, M. Mateos, A. Mazumder, R. Orlowski, H. Sutherland, J. Bladé, E. Scott, A. Oriol, J. Berdeja, M. Gharibo, D. Stevens, R. LeBlanc, M. Sebag, N. Callander, A. Jakubowiak, D. White, J. Rubia, P. Richardson, S. Lisby, Huaibao Feng, C. Uhlar, I. Khan, T. Ahmadi, P. Voorhees (2016)
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trialThe Lancet, 387
K. Yoshizawa, H. Mukai, Michiko Miyazawa, M. Miyao, Yoshimasa Ogawa, K. Ohyashiki, T. Katoh, M. Kusumoto, A. Gemma, F. Sakai, Y. Sugiyama, K. Hatake, Y. Fukuda, S. Kudoh (2014)
Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: Incidence, mortality and clinical characterizationCancer Science, 105
J. Laubach, P. Voorhees, H. Hassoun, A. Jakubowiak, S. Lonial, P. Richardson (2014)
Current strategies for treatment of relapsed/refractory multiple myelomaExpert Review of Hematology, 7
Daratumumab in combination with bortezomib and dexamethasone (DVd) has demonstrated longer progression-free survival than combination of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (RRMM). In this multicenter, open-label, phase-1 study, the safety, efficacy, and pharmacokinetics (PK) of DVd were evaluated in Japa - nese patients with RRMM. Eight patients with RRMM aged between 54 and 82 years were enrolled and treated with DVd regimen. Primary endpoints were tolerability and safety. Secondary endpoints were overall response rate (ORR), very good partial response (VGPR) or better, complete response (CR) or better, time to response (TTR), PK, and immunogenicity. All patients (n = 8) experienced Grade ≥ 3 treatment-emergent adverse events (TEAE), with thrombocytopenia (n = 6, 75%) being the most frequent. Mild Grade ≤ 2 infusion-related reactions were reported in five patients. Serious TEAEs were herpes zoster, nasopharyngitis, and prostate cancer (n = 1 each). Three dose-limiting toxicities were observed in two patients. No death or disease progression was reported as of the study cut-off date. ORR was 100% (2 CRs or better, 2 VGPRs, 4 PRs). The median TTR was 0.9 months. PK profiles were comparable to previous studies. The DVd regimen showed acceptable safety with favorable efficacy in Japanese patients with RRMM. Clinical trial registration number NCT02497378.
International Journal of Hematology – Springer Journals
Published: Dec 19, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.